Nimotuzumab Improves OS, PFS in KRAS Wild-Type Advanced Panc

Adding nimotuzumab to gemcitabine improves outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.

Related Keywords

China , Eileenm Oreilly , , Clinical Oncology ,